See more : Mo-BRUK S.A. (MBR.WA) Income Statement Analysis – Financial Results
Complete financial analysis of RaQualia Pharma Inc. (4579.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RaQualia Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Brunswick Exploration Inc. (BRWXF) Income Statement Analysis – Financial Results
- Kairuide Holding Co.Ltd (002072.SZ) Income Statement Analysis – Financial Results
- Fiserv, Inc. (FIV.DE) Income Statement Analysis – Financial Results
- Eni S.p.A. (ENI.MI) Income Statement Analysis – Financial Results
- Scrypt, Inc. (SYPT) Income Statement Analysis – Financial Results
RaQualia Pharma Inc. (4579.T)
About RaQualia Pharma Inc.
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.90B | 2.92B | 2.78B | 1.11B | 1.70B | 744.52M | 1.42B | 705.24M | 145.50M | 153.90M | 228.04M | 28.98M | 684.20M | 1.19B |
| Cost of Revenue | 245.05M | 231.59M | 320.67M | 138.01M | 262.80M | 89.41M | 149.53M | 117.63M | 53.35M | 2.55M | 307.00K | 0.00 | 11.43M | 101.73M |
| Gross Profit | 1.66B | 2.69B | 2.46B | 969.29M | 1.44B | 655.11M | 1.27B | 587.61M | 92.15M | 151.34M | 227.74M | 28.98M | 672.77M | 1.09B |
| Gross Profit Ratio | 87.11% | 92.06% | 88.45% | 87.54% | 84.57% | 87.99% | 89.46% | 83.32% | 63.33% | 98.34% | 99.87% | 100.00% | 98.33% | 91.43% |
| Research & Development | 1.37B | 1.25B | 1.13B | 932.45M | 864.25M | 1.07B | 848.52M | 796.23M | 1.30B | 1.52B | 1.52B | 1.80B | 1.66B | 1.65B |
| General & Administrative | 620.95M | 571.54M | 620.30M | 522.92M | 591.86M | 655.60M | 571.56M | 551.25M | 707.64M | 819.33M | 847.69M | 861.86M | 928.43M | 777.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 620.95M | 571.54M | 620.30M | 522.92M | 591.86M | 655.60M | 571.56M | 551.25M | 707.64M | 819.33M | 847.69M | 861.86M | 928.43M | 777.90M |
| Other Expenses | 0.00 | -211.00K | -848.00K | 2.11M | 1.05M | 4.00M | 45.05M | 21.44M | 1.26M | 5.54M | 269.88M | -255.66M | 38.35M | 72.07M |
| Operating Expenses | 1.99B | 1.82B | 1.75B | 1.46B | 1.46B | 1.73B | 1.42B | 1.35B | 2.01B | 2.33B | 2.37B | 2.67B | 2.59B | 2.43B |
| Cost & Expenses | 2.24B | 2.05B | 2.07B | 1.59B | 1.72B | 1.82B | 1.57B | 1.47B | 2.01B | 2.34B | 2.37B | 2.67B | 2.60B | 2.53B |
| Interest Income | 9.70M | 13.66M | 22.85M | 31.74M | 44.18M | 41.22M | 38.81M | 64.98M | 82.05M | 34.08M | 1.43M | 5.94M | 2.97M | 1.10M |
| Interest Expense | 6.68M | 6.00M | 1.45M | 436.00K | 11.76M | 1.41M | 12.92M | 0.00 | 6.40M | 12.92M | 8.49M | 0.00 | 22.82M | 5.70M |
| Depreciation & Amortization | 175.56M | 147.73M | 141.56M | 124.25M | 140.05M | 125.59M | 85.79M | 79.88M | 53.35M | 21.27M | 68.16M | 28.33M | 19.26M | 23.76M |
| EBITDA | -111.80M | 1.00B | 1.02B | -403.25M | 124.00M | -950.00M | -65.00M | -680.00M | -1.81B | -2.16B | -2.07B | -2.61B | -1.90B | -1.32B |
| EBITDA Ratio | -5.88% | 36.16% | 36.63% | -36.46% | 6.71% | -125.65% | -5.89% | -97.28% | -1,193.23% | -1,366.24% | -1,222.29% | -8,966.15% | -277.31% | -111.38% |
| Operating Income | -337.37M | 866.24M | 707.86M | -486.08M | -25.84M | -1.08B | -150.41M | -759.88M | -1.86B | -2.18B | -2.14B | -2.64B | -1.92B | -1.35B |
| Operating Income Ratio | -17.74% | 29.69% | 25.50% | -43.90% | -1.52% | -144.40% | -10.60% | -107.75% | -1,281.51% | -1,418.87% | -937.53% | -9,099.65% | -280.12% | -113.38% |
| Total Other Income/Expenses | 43.32M | -15.22M | 172.72M | -41.86M | 42.31M | -3.08M | 90.56M | 37.17M | 16.14M | 1.55B | 1.04B | -264.73M | 10.18M | 49.71M |
| Income Before Tax | -294.05M | 851.01M | 880.58M | -527.94M | 27.31M | -1.08B | -59.85M | -722.71M | -1.85B | -631.70M | -1.10B | -2.90B | -1.91B | -1.30B |
| Income Before Tax Ratio | -15.47% | 29.16% | 31.72% | -47.68% | 1.60% | -144.82% | -4.22% | -102.48% | -1,270.42% | -410.47% | -483.31% | -10,013.19% | -278.64% | -109.19% |
| Income Tax Expense | 29.61M | 127.62M | 124.79M | 79.04M | 21.97M | 26.36M | -1.73M | 5.41M | 5.89M | 7.22M | 6.11M | 3.84M | 9.84M | 11.84M |
| Net Income | -323.66M | 723.39M | 755.79M | -606.99M | 5.34M | -1.10B | -58.12M | -728.12M | -1.85B | -638.92M | -1.11B | -2.91B | -1.92B | -1.31B |
| Net Income Ratio | -17.02% | 24.79% | 27.22% | -54.82% | 0.31% | -148.36% | -4.10% | -103.24% | -1,274.47% | -415.17% | -485.99% | -10,026.44% | -280.07% | -110.19% |
| EPS | -14.98 | 34.50 | 36.07 | -28.97 | 0.26 | -54.23 | -2.99 | -38.80 | -116.45 | -45.70 | -82.70 | -219.00 | -172.85 | -261.12K |
| EPS Diluted | -14.98 | 34.47 | 36.04 | -28.97 | 0.26 | -54.23 | -2.99 | -38.80 | -116.45 | -45.70 | -82.70 | -219.00 | -172.85 | -261.12K |
| Weighted Avg Shares Out | 21.61M | 20.97M | 20.95M | 20.95M | 20.59M | 20.37M | 19.42M | 18.77M | 15.92M | 13.98M | 13.40M | 13.27M | 11.09M | 5.01K |
| Weighted Avg Shares Out (Dil) | 21.61M | 20.98M | 20.97M | 20.95M | 20.62M | 20.37M | 19.42M | 18.77M | 15.92M | 13.98M | 13.40M | 13.27M | 11.09M | 5.01K |
Source: https://incomestatements.info
Category: Stock Reports